This is the list of Schedule V drugs as defined by the United StatesControlled Substances Act.[1]
The following findings are required for drugs to be placed in this schedule:[2]
The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
The drug or other substance has a currently accepted medical use in treatment in the United States.
Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.
Cannabidiol, only in a marijuana-derived pharmaceutical formulation marketed by GW Pharmaceuticals as Epidiolex. Cannabidiol derived from industrial hemp remains schedule 1.[3]